Cargando…

Computational research of mTORC1 inhibitor on cerebral ischemia-reperfusion injury

Ischemic stroke contributes to more than 80% of all strokes and has the four characteristics of high prevalence, high disability, high mortality, and high recurrence. Stroke is a preventable and controllable disease. In addition to controlling the primary disease, effective prevention and control me...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hui, Yang, Wenzhuo, Wang, Zhenhua, Wang, Xu, Hao, Yulei, Xi, Jianxin, Lu, Han, Du, Zhishan, Feng, Jiachun, Zhang, Bao, Ma, Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386574/
https://www.ncbi.nlm.nih.gov/pubmed/34343111
http://dx.doi.org/10.18632/aging.203371
_version_ 1783742288391831552
author Li, Hui
Yang, Wenzhuo
Wang, Zhenhua
Wang, Xu
Hao, Yulei
Xi, Jianxin
Lu, Han
Du, Zhishan
Feng, Jiachun
Zhang, Bao
Ma, Di
author_facet Li, Hui
Yang, Wenzhuo
Wang, Zhenhua
Wang, Xu
Hao, Yulei
Xi, Jianxin
Lu, Han
Du, Zhishan
Feng, Jiachun
Zhang, Bao
Ma, Di
author_sort Li, Hui
collection PubMed
description Ischemic stroke contributes to more than 80% of all strokes and has the four characteristics of high prevalence, high disability, high mortality, and high recurrence. Stroke is a preventable and controllable disease. In addition to controlling the primary disease, effective prevention and control measures need to be given to the occurrence and development of stroke. With the development and progress of modern treatment methods for ischemic stroke, the mortality and disability rate have decreased significantly. At present, the main treatment methods for ischemic stroke include thrombolysis, thrombus removal at the ultra-early stage, and treatment of improving collateral circulation in the acute phase. However, the ultra-early and early blood reperfusion involves reperfusion injury, which will cause secondary nerve damage, which is called cerebral ischemia/reperfusion injury (CIRI). Studies have found that autophagy is involved in the entire process of CIRI and can reduce the damage of CIRI. The mammalian target of Rapamycin (mTORC1) is the primary signal pathway regulating autophagy. And the mTORC1 inhibitor, Rapamycin, has been proved to exert neuroprotective effects in the ultra-early and early cerebral ischemia-reperfusion. Therefore, screening and designing mTORC1 inhibitors is very important to control reperfusion injury and reduce neuronal death and apoptosis. In this research, plenty of computer-assisted was applied to virtually screen and select potential mTORC1’s inhibitors. We used Libdock to screen the structure and performed toxicity predictions, ADME (absorption, distribution, metabolism, excretion) to predict small molecules’ pharmacological and toxicological properties. To assess the binding mechanism and affinity between the mTORC1 dimer and the ligand, molecular docking was performed. Then, the pharmacophore of small molecules in the docking conformation with the protein was supplemented by Schrodinger. Additionally, molecular dynamics simulations were conducted to assess if the ligand-receptor complex was stable in a natural environment. Furthermore, an experiment was performed to verify the inhibitory effect of compound 1 and compound 2 on mTOR protein. All in all, the study provides a hand of candidate drugs as well as pharmacological properties, which can play an essential role in mTORC1 inhibitors.
format Online
Article
Text
id pubmed-8386574
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-83865742021-08-27 Computational research of mTORC1 inhibitor on cerebral ischemia-reperfusion injury Li, Hui Yang, Wenzhuo Wang, Zhenhua Wang, Xu Hao, Yulei Xi, Jianxin Lu, Han Du, Zhishan Feng, Jiachun Zhang, Bao Ma, Di Aging (Albany NY) Research Paper Ischemic stroke contributes to more than 80% of all strokes and has the four characteristics of high prevalence, high disability, high mortality, and high recurrence. Stroke is a preventable and controllable disease. In addition to controlling the primary disease, effective prevention and control measures need to be given to the occurrence and development of stroke. With the development and progress of modern treatment methods for ischemic stroke, the mortality and disability rate have decreased significantly. At present, the main treatment methods for ischemic stroke include thrombolysis, thrombus removal at the ultra-early stage, and treatment of improving collateral circulation in the acute phase. However, the ultra-early and early blood reperfusion involves reperfusion injury, which will cause secondary nerve damage, which is called cerebral ischemia/reperfusion injury (CIRI). Studies have found that autophagy is involved in the entire process of CIRI and can reduce the damage of CIRI. The mammalian target of Rapamycin (mTORC1) is the primary signal pathway regulating autophagy. And the mTORC1 inhibitor, Rapamycin, has been proved to exert neuroprotective effects in the ultra-early and early cerebral ischemia-reperfusion. Therefore, screening and designing mTORC1 inhibitors is very important to control reperfusion injury and reduce neuronal death and apoptosis. In this research, plenty of computer-assisted was applied to virtually screen and select potential mTORC1’s inhibitors. We used Libdock to screen the structure and performed toxicity predictions, ADME (absorption, distribution, metabolism, excretion) to predict small molecules’ pharmacological and toxicological properties. To assess the binding mechanism and affinity between the mTORC1 dimer and the ligand, molecular docking was performed. Then, the pharmacophore of small molecules in the docking conformation with the protein was supplemented by Schrodinger. Additionally, molecular dynamics simulations were conducted to assess if the ligand-receptor complex was stable in a natural environment. Furthermore, an experiment was performed to verify the inhibitory effect of compound 1 and compound 2 on mTOR protein. All in all, the study provides a hand of candidate drugs as well as pharmacological properties, which can play an essential role in mTORC1 inhibitors. Impact Journals 2021-08-03 /pmc/articles/PMC8386574/ /pubmed/34343111 http://dx.doi.org/10.18632/aging.203371 Text en Copyright: © 2021 Li et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Li, Hui
Yang, Wenzhuo
Wang, Zhenhua
Wang, Xu
Hao, Yulei
Xi, Jianxin
Lu, Han
Du, Zhishan
Feng, Jiachun
Zhang, Bao
Ma, Di
Computational research of mTORC1 inhibitor on cerebral ischemia-reperfusion injury
title Computational research of mTORC1 inhibitor on cerebral ischemia-reperfusion injury
title_full Computational research of mTORC1 inhibitor on cerebral ischemia-reperfusion injury
title_fullStr Computational research of mTORC1 inhibitor on cerebral ischemia-reperfusion injury
title_full_unstemmed Computational research of mTORC1 inhibitor on cerebral ischemia-reperfusion injury
title_short Computational research of mTORC1 inhibitor on cerebral ischemia-reperfusion injury
title_sort computational research of mtorc1 inhibitor on cerebral ischemia-reperfusion injury
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386574/
https://www.ncbi.nlm.nih.gov/pubmed/34343111
http://dx.doi.org/10.18632/aging.203371
work_keys_str_mv AT lihui computationalresearchofmtorc1inhibitoroncerebralischemiareperfusioninjury
AT yangwenzhuo computationalresearchofmtorc1inhibitoroncerebralischemiareperfusioninjury
AT wangzhenhua computationalresearchofmtorc1inhibitoroncerebralischemiareperfusioninjury
AT wangxu computationalresearchofmtorc1inhibitoroncerebralischemiareperfusioninjury
AT haoyulei computationalresearchofmtorc1inhibitoroncerebralischemiareperfusioninjury
AT xijianxin computationalresearchofmtorc1inhibitoroncerebralischemiareperfusioninjury
AT luhan computationalresearchofmtorc1inhibitoroncerebralischemiareperfusioninjury
AT duzhishan computationalresearchofmtorc1inhibitoroncerebralischemiareperfusioninjury
AT fengjiachun computationalresearchofmtorc1inhibitoroncerebralischemiareperfusioninjury
AT zhangbao computationalresearchofmtorc1inhibitoroncerebralischemiareperfusioninjury
AT madi computationalresearchofmtorc1inhibitoroncerebralischemiareperfusioninjury